Hypertrophic Cardiomyopathy Genotype Prediction Models in a Pediatric Population
The Toronto Hypertrophic Cardiomyopathy (HCM) Genotype Score and Mayo HCM Genotype Predictor are risk assessment models developed to estimate a patient’s likelihood of testing positive for a pathogenic variant causative of HCM. These models were developed from adult populations with HCM based on factors that have been associated with a positive genotype and have not been validated in external populations. The purpose of this study was to evaluate the overall predictive abilities of these models in a clinical pediatric HCM setting. A retrospective medical record review of 77 pediatric patients with gene panel testing for HCM between September 2005 and June 2015 was performed. Clinical and echocardiographic variables used in the developed models were collected and used to calculate scores for each patient. To evaluate model performance, the ability to discriminate between a carrier and non-carrier was assessed by area under the ROC curve (AUC) and overall calibration was evaluated by the Hosmer–Lemeshow goodness-of-fit statistic. Discrimination assessed by AUC was 0.72 (P < 0.001) for the Toronto model and 0.67 (P = 0.004) for the Mayo model. The Toronto model and the Mayo model showed P values of 0.36 and 0.82, respectively, for model calibration. Our findings suggest that these models are useful in predicting a positive genetic test result in a pediatric HCM setting. They may be used to aid healthcare providers in communicating risk and enhance patient decision-making regarding pursuit of genetic testing.
KeywordsHypertrophic cardiomyopathy Genotype Genetic testing Pediatrics Risk assessment Genetic counseling
Compliance with Ethical Standards
Conflict of interest
Erin M. Miller has served as a consultant for Ambry Genetics, a clinical genetic testing laboratory. Amy Shikany and John L. Jefferies have employment responsibilities with the Heart Institute Diagnostic Lab, a clinical genetic testing laboratory at Cincinnati Children’s Hospital Medical Center. The additional authors report no conflict of interest.
For this type of study formal consent is not required.
- 15.Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 13(8):1077–1109CrossRefPubMedGoogle Scholar
- 16.Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS et al (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124(24):e783–e831CrossRefPubMedGoogle Scholar
- 18.Fischer C, Kuchenbacker K, Engel C, Zachariae S, Rhiem K, Meindl A et al (2013) Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet 50:360–367CrossRefPubMedGoogle Scholar
- 23.Girolami F, Olivotto I, Passerini I, Zachara E, Nistri S, Re F et al (2006) A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med 7(8):601–607CrossRefGoogle Scholar
- 25.Murphy SL, Anderson JH, Kapplinger JD, Kruisselbrink TM, Gersh BJ, Ommen SR et al (2016) Evaluation of the Mayo Clinic phenotype-based genotype predictor score in patients with clinically diagnosed hypertrophic cardiomyopathy. J Cardiovasc Transl Res 9:153–161CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, Jang W, Katz K, Ovetsky M, Riley G, Sethi A, Tully R, Villamarin-Salomon R, Rubinstein W, Maglott DR (2015) ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 44:D862–D868CrossRefPubMedPubMedCentralGoogle Scholar
- 29.R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, ViennaGoogle Scholar